Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes GlobeNewswire - Tue Dec 17, 7:10AM CST

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call Presenting Topline Results from Phase II Trial of Icovamenib in Type 2 Diabetes Quiver Quantitative, Inc. - Tue Dec 17, 3:32AM CST

Biomea Fusion will discuss COVALENT-111 Phase II trial results for icovamenib in type 2 diabetes on December 17, 2024.Quiver AI SummaryBiomea Fusion, Inc. announced that it will host a conference call...

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) GlobeNewswire - Mon Dec 16, 5:15PM CST

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Promising Preclinical Results for Icovamenib in Enhancing Beta Cell Function and Synergy with GLP-1-Based Therapies Quiver Quantitative, Inc. - Fri Dec 13, 2:12AM CST

Icovamenib improves beta cell function and insulin secretion, enhancing effectiveness of GLP-1 therapies in diabetes treatment.Quiver AI SummaryBiomea Fusion, Inc. announced positive results from preclinical...

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) GlobeNewswire - Thu Dec 12, 4:02PM CST

BMEA : 4.23 (+3.68%)
Biomea Fusion, Inc. Announces Promising Preliminary Phase I Data for BMF-500 in Treating Relapsed or Refractory Acute Leukemia with FLT3 Mutations Quiver Quantitative, Inc. - Tue Dec 10, 1:22AM CST

Preliminary data indicates BMF-500 may effectively treat R/R acute leukemia with FLT3 mutations, showing promising safety and efficacy.Quiver AI SummaryBiomea Fusion, Inc. has announced promising preliminary...

BMEA : 4.23 (+3.68%)
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia GlobeNewswire - Mon Dec 9, 3:01PM CST

BMEA : 4.23 (+3.68%)
Biomea Fusion to Present Data from Phase I Trial of BMF-500 for Acute Leukemia on December 9, 2024 Quiver Quantitative, Inc. - Fri Dec 6, 5:22PM CST

Biomea Fusion announces a conference call to present Phase I trial data for BMF-500 in acute leukemia on December 9, 2024.Quiver AI SummaryBiomea Fusion, Inc., a biopharmaceutical company focused on developing...

BMEA : 4.23 (+3.68%)
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia GlobeNewswire - Fri Dec 6, 7:00AM CST

BMEA : 4.23 (+3.68%)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Dec 2, 3:05PM CST

BMEA : 4.23 (+3.68%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot